BioWorld

May 7, 2003

Testing Primates' Visual Response Against Flagging GABA In Cerebral Cortex Reveals New Drug Resource

Neurogenetics Licenses Rights To Pain Compound From Lilly

Incyte Reports Falling Revenue; Splits Discovery, Information Units

Other News To Note

SARS: Revenue Generator Or Flash-In-The-Pan Illness?

Biotechnology oftentimes eases into the wake of U.S. - and global - burgeoning health risks. That wake occasionally allows companies to ride the waves of newfound investor interest. (BioWorld Today) Read More

European Sector Experiences Falloff In Revenues, Employees

Today's news in brief

BioWorld

BioWorld briefs for June 26, 2026.

Brain-computer interfaces are here but long road ahead

BioWorld

The field of BCI is continually evolving; as such, companies are increasingly highlighting the potential of their technologies to transform care. For advanced...

Next wave of BCI firms builds on pioneers to tackle challenges

BioWorld

With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...

Boehringer Ingelheim identifies new mGlu3 receptor agonists

BioWorld Science

Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...

Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

ENCALS 2026: From genetics to advancing strategies against ALS

BioWorld Science

Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...